In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company ...

Oncology has been an easy area for employers to adopt biosimilars because of the rising costs in the space, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. (Bloomberg) — AbbVie Inc.’s blockbuster drug Humira costs ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

Several biosimilar generic competitors will hit the market in 2023. Humira has been AbbVie's most significant product by far. The growth of emerging products should keep the dividend intact. Humira is ...

After 20 years and $200 billion in revenue, Humira — an injectable treatment for rheumatoid arthritis and several other autoimmune conditions — has lost its monopoly. Early Tuesday morning, California ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Patients who take the autoimmune disease ...

This was expected to be the year that Humira, AbbVie ‘s blockbuster $90,000-a-year arthritis treatment and the best-selling biopharmaceutical in history, loses its chokehold on the healthcare system.